Prescription medicine
Efavirenz and emtricitabine and tenofovir disoproxil First approved as Atripla
Efavirenz and emtricitabine and tenofovir disoproxil (Atripla) is a prescription medicine with an FDA approval on record since 2006. FDA's NDC Directory lists it from 7 generic labelers, and pharmacies paid $1.12 per efavirenz-emtricitabine-tenofov disop fum 600-200-300 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the efavirenz and emtricitabine and tenofovir disoproxil FDA label on DailyMed (effective July 28, 2025, Laurus Labs Limited); the NDA 21937 record on Drugs@FDA; every efavirenz and emtricitabine and tenofovir disoproxil label on DailyMed.
Highlights of the record
FDA label of July 28, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B.
Severe acute exacerbations of hepatitis B virus (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), which are components of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B virus (HBV) have been reported in patients coinfected with HBV and HIV-1 who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. […]
Used for
From the label: indications and usageEfavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
Forms and strengths
- 600 mg / 200 mg / 300 mg
Film-coated tablet.
On the market
- Earliest approval on file
- July 12, 2006 Atripla, Gilead Sciences; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 8 first September 4, 2018; 7 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 7 of which 7 under generic applications, 0 under brand applications, repackagers included
- Last listed patent
- April 28, 2029 Atripla tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $1.12 per tablet Efavirenz-emtricitabine-tenofov disop fum 600-200-300 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 47 through July 30, 2026
What is efavirenz and emtricitabine and tenofovir disoproxil used for?
From the label: indications and usageEfavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. […]
Conditions named in the indications of efavirenz and emtricitabine and tenofovir disoproxil's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
Source: FDA drug label (Efavirenz, emtricitabine and tenofovir disoproxil fumarate), Laurus Labs Limited, effective July 28, 2025 (SPL set aca22076-f435-4533-9fcf-566b0734c313), via openFDA; the full label on DailyMed
What does the patient leaflet for efavirenz and emtricitabine and tenofovir disoproxil say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets?Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets can cause serious side effects, including: ● Worsening of hepatitis B virus (HBV) infection. Your healthcare provider will test you for HBV before starting treatment with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. If you have HBV infection and take efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets, your HBV may get worse (flare-up) if you stop taking efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. ○ Do not stop taking efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets without first talking with your healthcare provider. ○ Do not run out of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. Refill your prescription or talk to your healthcare provider before your efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are all gone. ○ If you stop taking efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection, or give you a medication to treat hepatitis B. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. For more information about side effects see the section, “What are the possible side effects of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets?”
From the patient leaflet: What should I avoid while taking efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets?Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets can cause dizziness, impaired concentration and drowsiness. If you have these symptoms, do not drive a car, use heavy machinery, or do anything that requires you to be alert.
From the patient leaflet: How should I store efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets?Store efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets in its original container and keep the container tightly closed. Keep efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets and all other medicines out of reach of children.
Source: FDA drug label (Efavirenz, emtricitabine and tenofovir disoproxil fumarate), Laurus Labs Limited, effective July 28, 2025 (SPL set aca22076-f435-4533-9fcf-566b0734c313), via openFDA; the full label on DailyMed
Is there a generic for efavirenz and emtricitabine and tenofovir disoproxil (Atripla)?
The FDA approved the first generic efavirenz and emtricitabine and tenofovir disoproxil on September 4, 2018. 8 generic applications are approved; 7 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists efavirenz and emtricitabine and tenofovir disoproxil from 7 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 3 patents for Atripla tablets, the last expiring on April 28, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2006 earliest approval on file
- 2018 first generic approved
- 2029 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for efavirenz and emtricitabine and tenofovir disoproxil (Atripla)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.12 per Efavirenz-emtricitabine-tenofov disop fum 600-200-300 mg tablet, down 22% from $1.45 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Efavirenz-emtricitabine-tenofov disop fum 600-200-300 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Efavirenz-emtricitabine-tenofov disop fum 600-200-300 mg tablet | Generic | $1.12 per tablet | $33.75 | -22% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the efavirenz and emtricitabine and tenofovir disoproxil label say about other medicines?
The efavirenz and emtricitabine and tenofovir disoproxil label names 52 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acyclovir | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.7) ]. |
| Adefovir dipivoxil | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.7) ]. |
| Artemether and lumefantrine | drug interactions | Antimalarials: artemether/ lumefantrine atovaquone/proguanil ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine ↓ atovaquone ↓ proguanil Consider alternatives to artemether/lumefantrine because of the risk of QT interval prolongation [see Warnings and Precautions (5.4) ]. |
| Atazanavir | drug interactions | Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with either atazanavir or atazanavir and ritonavir is not recommended. |
| Atorvastatin | drug interactions | Concomitant Drug Class/Drug Name: HMG-CoA reductase inhibitors: atorvastatin pravastatin simvastatin; Effect: ↓ atorvastatin ↓ pravastatin ↓ simvastatin; Clinical Comment: Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased with EFV. … |
| Atovaquone | drug interactions | Concomitant Drug Class/Drug Name: Antimalarials: artemether/ lumefantrine atovaquone/proguanil; Effect: ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine ↓ atovaquone ↓ proguanil; Clinical Comment: Consider alternatives to artemether/lumefantrine because of the risk of QT interval prolongation [see ]. … |
| Atovaquone and proguanil | drug interactions | Antimalarials: artemether/ lumefantrine atovaquone/proguanil ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine ↓ atovaquone ↓ proguanil Consider alternatives to artemether/lumefantrine because of the risk of QT interval prolongation [see Warnings and Precautions (5.4) ]. |
| Bupropion | drug interactions | Concomitant Drug Class/Drug Name: Antidepressants: bupropion; Effect: ↓ bupropion; Clinical Comment: The effect of EFV on bupropion exposure is thought to be due to the induction of bupropion metabolism. … |
| Carbamazepine | drug interactions | Concomitant Drug Class/Drug Name: Anticonvulsants: carbamazepine; Effect: ↓ carbamazepine ↓ efavirenz; Clinical Comment: There are insufficient data to make a dose recommendation for efavirenz, emtricitabine and tenofovir disoproxil fumarate. Alternative anticonvulsant treatment should be used. |
| Cidofovir | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.7) ]. |
| Clarithromycin | drug interactions | Concomitant Drug Class/Drug Name: Anti-infective: clarithromycin; Effect: ↓ clarithromycin ↑ 14-OH metabolite; Clinical Comment: Consider alternatives to macrolide antibiotics because of the risk of QT interval prolongation. |
| Cyclosporine | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A; Effect: ↓ immuno- suppressant; Clinical Comment: Decreased exposure of the immunosuppressant may be expected due to CYP3A induction by EFV. … |
| Darunavir | drug interactions | Concomitant Drug Class/Drug Name: Protease inhibitor: darunavir/ritonavir lopinavir/ritonavir; Effect: ↑tenofovir ↓lopinavir ↑tenofovir; Clinical Comment: Monitor patients receiving efavirenz, emtricitabine and tenofovir disoproxil fumarate concomitantly with ritonavir-boosted darunavir for TDF-associated adverse … |
| Diltiazem | drug interactions | Concomitant Drug Class/Drug Name: Calcium channel blockers: diltiazem; Effect: ↓ diltiazem ↓ desacetyl diltiazem ↓ N-monodes- methyl diltiazem; Clinical Comment: Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem). … |
Every other medicine the efavirenz and emtricitabine and tenofovir disoproxil label names
| Medicine named | Section | What the label says |
|---|---|---|
| Elbasvir and grazoprevir | contraindications | Efavirenz, emtricitabine and tenofovir disoproxil fumarate is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see Drug Interactions (7.3) and Clinical Pharmacology … |
| Etonogestrel | drug interactions | Concomitant Drug Class/Drug Name: Hormonal contraceptives: Oral: ethinyl estradiol/norgestimate Implant: etonogestrel; Effect: ↓ active metabolites of norgestimate ↓ etonogestrel; … |
| Felodipine | drug interactions | Concomitant Drug Class/Drug Name: Others e.g., felodipine nicardipine nifedipine verapamil; Effect: ↓ calcium channel blocker; … |
| Fosamprenavir | drug interactions | Concomitant Drug Class/Drug Name: Protease inhibitor: fosamprenavir calcium; Effect: ↓amprenavir; Clinical Comment: Fosamprenavir (unboosted): Appropriate doses of fosamprenavir and efavirenz … |
| Ganciclovir | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple … |
| Gentamicin | drug interactions | … ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.7) ]. |
| Glecaprevir and pibrentasvir | drug interactions | The combination should be avoided. elbasvir/grazoprevir ↓ elbasvir ↓ grazoprevir Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with elbasvir/grazoprevir is … |
| Itraconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: itraconazole; Effect: ↓ itraconazole ↓ hydroxy- itraconazole; Clinical Comment: Since no dose recommendation for itraconazole can be made, alternative … |
| Ketoconazole | drug interactions | Concomitant Drug Class/Drug Name: ketoconazole; Effect: ↓ ketoconazole; Clinical Comment: Drug interaction trials with efavirenz, emtricitabine and tenofovir disoproxil fumarate and ketoconazole have … |
| Lamivudine | warnings and precautions | … 102 weeks, and 76 weeks for subjects treated with EFV + zidovudine + lamivudine, EFV + indinavir, and indinavir + zidovudine + lamivudine, respectively), treatment with EFV was associated with an … |
| Ledipasvir and sofosbuvir | drug interactions | The combination should be avoided. elbasvir/grazoprevir ↓ elbasvir ↓ grazoprevir Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with elbasvir/grazoprevir is … |
| Levonorgestrel | drug interactions | Efavirenz had no effect on ethinyl estradiol concentrations, but progestin levels (norelgestromin and levonorgestrel) were markedly decreased. |
| Lopinavir and ritonavir | drug interactions | Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with either lopinavir/ritonavir or darunavir and ritonavir increases tenofovir concentrations. … |
| Maraviroc | drug interactions | Concomitant Drug Class/Drug Name: CCR5 co-receptor antagonist: maraviroc; Effect: ↓maraviroc; Clinical Comment: Refer to the full prescribing information for maraviroc for guidance on … |
| Methadone | drug interactions | Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms. |
| Nevirapine | warnings and precautions | Nineteen subjects who discontinued nevirapine because of rash have been treated with EFV. |
| Nicardipine | drug interactions | Concomitant Drug Class/Drug Name: Others e.g., felodipine nicardipine nifedipine verapamil; Effect: ↓ calcium channel blocker; … |
| Nifedipine | drug interactions | Concomitant Drug Class/Drug Name: Others e.g., felodipine nicardipine nifedipine verapamil; Effect: ↓ calcium channel blocker; … |
| Phenobarbital | drug interactions | Concomitant Drug Class/Drug Name: phenytoin phenobarbital; Effect: ↓ anticonvulsant ↓efavirenz; Clinical Comment: Potential for reduction in anticonvulsant and/or EFV plasma levels; … |
| Phenytoin | drug interactions | Concomitant Drug Class/Drug Name: phenytoin phenobarbital; Effect: ↓ anticonvulsant ↓efavirenz; Clinical Comment: Potential for reduction in anticonvulsant and/or EFV plasma levels; … |
| Posaconazole | drug interactions | Concomitant Drug Class/Drug Name: posaconazole; Effect: ↓ posaconazole; Clinical Comment: Avoid concomitant use unless the benefit outweighs the risks. |
| Pravastatin | drug interactions | Concomitant Drug Class/Drug Name: HMG-CoA reductase inhibitors: atorvastatin pravastatin simvastatin; Effect: ↓ atorvastatin ↓ pravastatin ↓ simvastatin; … |
| Raltegravir | drug interactions | Concomitant Drug Class/Drug Name: Integrase strand transfer inhibitor: raltegravir; Effect: ↓ raltegravir; Clinical Comment: The clinical significance of this interaction has not been directly … |
| Rifabutin | drug interactions | Concomitant Drug Class/Drug Name: Antimycobacterial: rifabutin; Effect: ↓ rifabutin; Clinical Comment: Increase daily dose of rifabutin by 50%. … |
| Rifampin | drug interactions | Concomitant Drug Class/Drug Name: rifampin; Effect: ↓ efavirenz; Clinical Comment: If efavirenz, emtricitabine and tenofovir disoproxil fumarate is coadministered with rifampin to patients weighing … |
| Ritonavir | drug interactions | … data to support dosing recommendations for atazanavir or atazanavir/ritonavir in combination with efavirenz, emtricitabine and tenofovir disoproxil fumarate. |
| Sertraline | drug interactions | Concomitant Drug Class/Drug Name: sertraline; Effect: ↓ sertraline; Clinical Comment: Increases in sertraline dose should be guided by clinical response. |
| Simvastatin | drug interactions | Concomitant Drug Class/Drug Name: HMG-CoA reductase inhibitors: atorvastatin pravastatin simvastatin; Effect: ↓ atorvastatin ↓ pravastatin ↓ simvastatin; … |
| Sirolimus | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A; Effect: ↓ immuno- suppressant; … |
| Sofosbuvir and velpatasvir | drug interactions | The combination should be avoided. elbasvir/grazoprevir ↓ elbasvir ↓ grazoprevir Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with elbasvir/grazoprevir is … |
| Sofosbuvir and velpatasvir and voxilaprevir | drug interactions | The combination should be avoided. elbasvir/grazoprevir ↓ elbasvir ↓ grazoprevir Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate with elbasvir/grazoprevir is … |
| Tacrolimus | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A; Effect: ↓ immuno- suppressant; … |
| Valacyclovir | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple … |
| Valganciclovir | drug interactions | Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple … |
| Verapamil | drug interactions | Concomitant Drug Class/Drug Name: Others e.g., felodipine nicardipine nifedipine verapamil; Effect: ↓ calcium channel blocker; … |
| Voriconazole | contraindications | Efavirenz, emtricitabine and tenofovir disoproxil fumarate is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see Drug Interactions (7.3) and Clinical Pharmacology … |
| Warfarin | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulant: warfarin; Effect: ↑ or ↓ warfarin; Clinical Comment: Plasma concentrations and effects potentially increased or decreased by EFV. |
| Zidovudine | warnings and precautions | … 180 weeks, 102 weeks, and 76 weeks for subjects treated with EFV + zidovudine + lamivudine, EFV + indinavir, and indinavir + zidovudine + lamivudine, respectively), treatment with EFV was associated … |
Check efavirenz and emtricitabine and tenofovir disoproxil against other medicines
Source: FDA drug label (Efavirenz, emtricitabine and tenofovir disoproxil fumarate), Laurus Labs Limited, effective July 28, 2025 (SPL set aca22076-f435-4533-9fcf-566b0734c313), via openFDA; the full label on DailyMed
What do FAERS reports show for efavirenz and emtricitabine and tenofovir disoproxil?
The FDA Adverse Event Reporting System holds 47 reports that list efavirenz and emtricitabine and tenofovir disoproxil among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 16 are coded as a death and 20 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as efavirenz and emtricitabine and tenofovir disoproxil?
30 other medicines are given the same way (oral) and in the same FDA class as efavirenz and emtricitabine and tenofovir disoproxil or labeled mainly for the same use (HIV), the same class first. HIV lists all 47 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lamivudine | HIV | 14 labelers | $0.489 per tablet 150 mg tablet | No current entry |
| Etravirine | HIV | 5 labelers | $9.94 per tablet 200 mg tablet | A presentation being discontinued |
| Abacavir | HIV | 12 labelers | $0.546 per tablet 300 mg tablet | No current entry |
| Lamivudine and zidovudine | HIV | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | No current entry |
| Nevirapine | HIV | 6 labelers | $0.147 per tablet 200 mg tablet | No current entry |
| Zidovudine | HIV | 3 labelers | $0.464 per tablet 300 mg tablet | No current entry |
| Abacavir and lamivudine | HIV | 6 labelers | $1.48 per unit 600-300 mg | No current entry |
| Rilpivirine | HIV | 2 labelers | $48.04 per tablet 25 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to efavirenz and emtricitabine and tenofovir disoproxil
- 30 medicines for the same use
- Other hepatitis b virus nucleoside analog reverse transcriptase inhibitors
- the pharmacologic class, with prices and generics
- Efavirenz and emtricitabine and tenofovir disoproxil side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other